MannKind (MNKD)
(Delayed Data from NSDQ)
$5.05 USD
-0.14 (-2.70%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.06 +0.01 (0.20%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum C VGM
Brokerage Reports
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 21 - 40 ( 229 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
3Q21: Expect TyvasoDPI Approval and Launch by Mid-2022, While Partner Grows Opportunity in the Meantime; Raise to $6.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
TyvasoDPI Speedbump; Partner United Projects Rapid CRL Resolution and Launch By Summer
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
TyvasoDPI - October PDUFA - Now Driving the Story; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q21: Now Well-Financed and Potential Game-Changing Tyvaso DPI on File; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Partner?s Tyvaso PH-ILD Approval Tees up TyvasoDPI Filing and Transformational Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Finally Adding TreT to our Model; Raise PT to $6.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
2Q20: In-Line Afrezza Despite Prior Quarter Pull-Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Solid 1Q; Expect Post-COVID Afrezza Growth; TreT Opporutnity Could Take Shape by Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
4Q19 Afrezza Beat; TreT Opportunity Likely Underappreciated
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
2Q19 Afrezza Growing, Albeit Slowly; Recapitalization Provides Potential Runway to Breakeven; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q19 Results: Better Than Prescriptions Portended; But Still Awaiting Real Inflection; Lower Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
4Q18 Results; Clean Afrezza Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O